Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - estradiol valerate - oral tablet - 1mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

necessity supplies ltd - estradiol valerate - oral tablet - 1mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - estradiol valerate - oral tablet - 1mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

pilsco ltd - estradiol valerate - oral tablet - 1mg

Малайзия - английски - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bayer co. (malaysia) sdn. bhd. - estradiol valerate -

Малта - английски - Malta Medicines Authority

miller and miller chemicals unit 3, burnside industrial est, 49-53 roebuck road hainault, essex ig63ug, united kingdom - estradiol valerate - tablet - estradiol valerate 1 mg - sex hormones and modulators of the genital system

Малта - английски - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - estradiol valerate - coated tablet - estradiol valerate 1 mg - sex hormones and modulators of the genital system

Австралия - английски - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - oestradiol valerate - unknown - oestradiol valerate steroid-estrogen active 0.0 - active constituent

САЩ - английски - NLM (National Library of Medicine)

physicians total care, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 1 mg - estradiol/norethindrone acetate tablets 1.0 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in women who have a uterus for the: - treatment of moderate to severe vasomotor symptoms associated with menopause. - prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. the mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin d intake, and when indicated, pharmacologic therapy. postmenopausal women require an average of 1500 mg/day of elemental calcium. therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. vitamin d supplementation of 400-800 iu/day may also be required to ensure adequate daily intake in postmenopausal women. estradiol/norethindrone acetate tablets 1.0 mg/0.5 mg is also in

САЩ - английски - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 1 mg - estradiol/norethindrone acetate tablets are indicated for:   limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. estradiol/norethindrone acetate tablets are contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding [see warnings and precautions (5.2)] - breast cancer or history of breast cancer [see warnings and precautions (5.2)] - estrogen-dependent neoplasia [see warnings and precautions (5.2)] - active dvt, pe, or history of these conditions [see warnings and precautions (5.1)] - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions [see warnings and precauti